Weiss & Lurie, a national class action and shareholder rights law firm with offices in New York City and Los Angeles, is investigating possible breaches of fiduciary duty and other violations of law by members of the Board of Directors of Dionex Corp (NASDAQ: DNEX) arising from the proposed acquisition of Dionex by Thermo Fisher Scientific Inc. (NYSE: TMO). Under the terms of the transaction, Dionex shareholders will receive $118.50 in cash for each share of Dionex. The total value of the transaction is approximately $2.1 billion. The transaction is expected to close in the first quarter of 2011. Weiss & Lurie is investigating whether Dionex’s Board acted in the best interests of shareholders in approving the proposed transaction and whether Dionex’s Board properly sought to maximize shareholder value. If you own common stock in Dionex and would like more information about your rights as a shareholder or additional information concerning our investigation, please contact Michael A. Rogovin either by email at firstname.lastname@example.org or by telephone at (888) 593-4771. Weiss & Lurie has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded institutions and individuals and obtained important corporate governance in these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (such as insider trading, waste of corporate assets, accounting fraud, or issuing materially misleading press releases or SEC filings), consumer fraud (such as false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at email@example.com or fill out the form on our website, http://www.weisslurie.com/contact/report_fraud/. Attorney Advertising. Past results do not guarantee a similar outcome.